The pan-HDAC inhibitor SAHA is currently in clinical trials for GBM, but results so far showed marginal improvement in overall survival (5.7 months compared to 4.4 months) and several serious side effects6–9,43,44. The gene discussed is HDAC9; the disease is glioblastoma.